Latest stories on JBIO
Jade Biosciences, Inc. (JBIO) files 8-K
SEC 8-K50 · neutralgeneral
Jade Biosciences reports Q2 EPS (76c) vs. (86c) last year
The Fly53 · neutralearnings
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
StockTitan50 · neutralgeneral
Jade Biosciences, Inc. (JBIO) files 8-K
SEC 8-K50 · neutralgeneral
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
Yahoo Top63 · neutralanalyst
Jade Biosciences Adds Veteran Biopharma Leader to Board
TipRanks56 · neutralgeneral
Jade Biosciences, Inc. (JBIO) files 8-K
SEC 8-K50 · neutralgeneral
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors | JBIO Stock News
StockTitan56 · neutralgeneral
Jade Biosciences, Inc. (JBIO) files 8-K
SEC 8-K50 · neutralgeneral
Jade Biosciences Launches Major Underwritten Equity Offering
TipRanks28 · bearishgeneral
Jade Biosciences Prices $150 Million Public Offering—Funding Accelerates Autoimmune Pipeline Ambitions
MarketChameleon24 · bearishgeneral
Jade Biosciences prices $150M public offering of common stock at $15/share
Seeking Alpha24 · bearishgeneral
Jade Biosciences Announces Pricing of Public Offering of Common Stock | JBIO Stock News
StockTitan24 · bearishgeneral
Jade Biosciences plans public offering, pre-funded warrants
Seeking Alpha24 · bearishgeneral
Jade Biosciences Announces Proposed Underwritten Public Offering | JBIO Stock News
StockTitan24 · bearishgeneral
Jade Biosciences: Strong Early Signal, But Still A Wait For Proof
Seeking Alpha58 · neutralgeneral
Jade Biosciences Reports Positive Phase 1 JADE101 Results
TipRanks73 · bullishproduct/pr
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy | JBIO Stock News
StockTitan56 · neutralproduct/pr